Key Data Updates in Multiple Myeloma from ASH 2023

home / data-dialogue-with-the-oncology-brothers / key-data-updates-in-multiple-myeloma-from-ash-2023

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss key data updates in multiple myeloma presented at the 2023 ASH Annual Meeting.

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 1: PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD
December 19th 2023

Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 2: IsKia: Isa-KRd vs KRd as Pre-Transplant Induction and Post-Transplant Consolidation in NDMM

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD
December 19th 2023

Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 3: Retrospective Study on Bortezomib Dosing in NDMM

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD
December 19th 2023

Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 4: KarMMA-3: Ide-Cel vs Standard Regimens in Triple-Class–Exposed RRMM

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD
December 19th 2023

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Jens Hillengass, MD, PhD; Rohit Gosain, MD; and Rahul Gosain, MD, presenting slides

EP. 5: Key Takeaways on Recent Data in Multiple Myeloma from ASH 2023

Rahul Gosain, MD;Rohit Gosain, MD;Jens Hillengass, MD, PhD
December 19th 2023

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.